Sign in

CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company

Aquestive Therapeutics, Inc.

Sign in to watch
Ticker
AQST
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
208623253
Phone
908-941-1900
Business address
184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
Former names
MonoSol Rx, Inc.
Open-market buys, last 90 days
$99,331
in 1 filing
Open-market sales, last 90 days
$378,930
in 4 filings, $379K under 10b5-1 plans

Net −$279,599. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Barber Daniel −$333K President and CEO sold 11% of stake
  2. Daly Richard J +$99K Director 1 filing
  3. Korczynski Sherry −$46K Chief Commercial Officer sold 4% of stake
Date Insider Transaction Shares Price Value Owned after
2018-08-31 Schobel Alexander Mark Chief Innovation/Tech Officer Option exercise +14,572 1,014,572
2018-08-31 Schobel Alexander Mark Chief Innovation/Tech Officer Shares withheld for taxes −6,510 $18.01 $117K 1,008,062
2018-08-31 Schobel Alexander Mark Chief Innovation/Tech Officer Option exercise · Restricted Stock Unit −14,572 102,004
2018-08-15 Schobel Alexander Mark Chief Innovation/Tech Officer Grant or award · Stock Option (Right to Purchase) +28,043 28,043
2018-08-15 Schobel Alexander Mark Chief Innovation/Tech Officer Grant or award · Restricted Stock Unit +2,636 2,636
2018-08-15 Kendall Keith J CEO and President Grant or award · Stock Option (Right to Purchase) +28,043 28,043
2018-08-15 Kendall Keith J CEO and President Grant or award · Restricted Stock Unit +2,636 2,636
2018-07-24 Wood Theresa SVP-HR and Org. Development Grant or award · Stock Option (Right to Purchase) +1,958 1,958
2018-07-24 COSTA SANTO J Director Grant or award · Stock Option (Right to Purchase) +26,700 26,700
2018-07-24 Boyd Peter E. SVP-Operations/Value Delivery Grant or award · Stock Option (Right to Purchase) +36,223 36,223
2018-07-24 Lurker Nancy Director Grant or award · Stock Option (Right to Purchase) +26,700 26,700
2018-07-24 Kendall Keith J CEO and President Grant or award · Stock Option (Right to Purchase) +240,165 240,165
2018-07-24 Kendall Keith J CEO and President Grant or award · Restricted Stock Unit +116,576 116,576
2018-07-24 Maxwell John T. SVP-Chief Financial Officer Grant or award · Stock Option (Right to Purchase) +36,120 36,120
2018-07-24 Cochran John Director Grant or award · Stock Option (Right to Purchase) +26,700 26,700
2018-07-24 Scibetta James S Director Grant or award · Stock Option (Right to Purchase) +26,700 26,700
2018-07-24 BROWN GREGORY B Director Grant or award · Stock Option (Right to Purchase) +26,700 26,700
2018-07-24 BRATTON DOUGLAS K Director Grant or award · Stock Option (Right to Purchase) +26,700 26,700
2018-07-24 Barber Daniel SVP-Chief Strategy/Dev Officer Grant or award · Stock Option (Right to Purchase) +96,507 96,507
2018-07-24 Schobel Alexander Mark Chief Innovation/Tech Officer Grant or award · Stock Option (Right to Purchase) +240,165 240,165

Page 23 of 24 · 462 trades